LILRB1-based chimeric antigen receptor

A chimeric antigen receptor comprising a polypeptide comprising:

• a) an antigen binding domain comprising an scFv comprising a CDR-L1, a CDR-L2, a CDR-L3, a CDR-H1, a CDR-H2, and a CDR-H3, wherein
• i) the CDR-L1 comprises SEQ ID NO:
• 22, the CDR-L2 comprises SEQ ID NO:
• 23, the CDR-L3 comprises SEQ ID NO:
• 24, the CDR-H1 comprises SEQ ID NO:
• 25, the CDR-H2 comprises SEQ ID NO:
• 26, and the CDR-H3 comprises SEQ ID NO:
• 27;
• or
• ii) the CDR-L1 comprises SEQ ID NO:
• 28, the CDR-L2 comprises SEQ ID NO:
• 29, the CDR-L3 comprises SEQ ID NO:
• 30, the CDR-H1 comprises SEQ ID NO:
• 31, the CDR-H2 comprises SEQ ID NO:
• 32, and the CDR-H3 comprises SEQ ID NO:
• 33;
• b) an LILRB1 hinge domain comprising SEQ ID NO:
• 4, SEQ ID NO:
• 18, SEQ ID NO:
• 19, SEQ ID NO:
• 80, SEQ ID NO:
• 81, SEQ ID NO:
• 82, SEQ ID NO:
• 83, SEQ ID NO:
• 84, SEQ ID NO:
• 93, or a sequence having at least 95% identity thereto;
• c) a transmembrane domain comprising SEQ ID NO:
• 5 or a sequence having at least 95% identity thereto;
• and
• d) an LILRB1 intracellular domain comprising at least one immunoreceptor tyrosine-based inhibitory motif (ITIM) selected from the group consisting of NLYAAV (SEQ ID NO:
• 8), VTYAEV (SEQ ID NO:
• 9), VTYAQL (SEQ ID NO:
• 10), and SIYATL (SEQ ID NO:
• 11).